$2.17
2.12% yesterday
Nasdaq, Dec 03, 10:08 pm CET
ISIN
US7602731025
Symbol
RPTX

Repare Therapeutics Inc Stock price

$2.17
+0.33 17.93% 1M
+0.72 49.66% 6M
+0.86 65.65% YTD
-1.04 32.40% 1Y
-14.32 86.84% 3Y
-32.99 93.83% 5Y
-28.63 92.95% 10Y
-28.63 92.95% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.05 2.12%
ISIN
US7602731025
Symbol
RPTX
Industry

Key metrics

Basic
Market capitalization
$91.3m
Enterprise Value
$-18.1m
Net debt
positive
Cash
$109.5m
Shares outstanding
43.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
365.4 | 8.7
EV/Sales
negative | negative
EV/FCF
0.2
P/B
0.8
Financial Health
Equity Ratio
85.6%
Return on Equity
-56.0%
ROCE
-102.9%
ROIC
-853.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$250.0k | $10.5m
EBITDA
$-110.5m | $-85.9m
EBIT
$-113.6m | $-72.0m
Net Income
$-109.9m | $-61.7m
Free Cash Flow
$-102.9m
Growth (TTM | estimate)
Revenue
-99.6% | -80.5%
EBITDA
-18.4% | 4.8%
EBIT
-19.3% | 21.9%
Net Income
-59.4% | 27.2%
Free Cash Flow
-28.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-44,188.8% | -821.2%
EBIT
-45,450.0%
Net
-43,945.6% | -590.1%
Free Cash Flow
-41,168.0%
More
EPS
$-2.6
FCF per Share
$-2.4
Short interest
1.8%
Employees
129
Rev per Employee
$410.0k
Show more

Is Repare Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,097 stocks worldwide.

Repare Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Repare Therapeutics Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Repare Therapeutics Inc forecast:

Buy
78%
Hold
22%

Financial data from Repare Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.25 0.25
100% 100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
21% 21%
10,572%
- Research and Development Expense 87 87
33% 33%
34,980%
-110 -110
18% 18%
-44,188%
- Depreciation and Amortization 3.15 3.15
58% 58%
1,260%
EBIT (Operating Income) EBIT -114 -114
19% 19%
-45,450%
Net Profit -110 -110
59% 59%
-43,944%

In millions USD.

Don't miss a Thing! We will send you all news about Repare Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repare Therapeutics Inc Stock News

Neutral
Business Wire
13 days ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company,...
Neutral
GlobeNewsWire
15 days ago
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Neutral
Business Wire
19 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Repare Therapeutics Inc. (NASDAQ: RPTX) to XenoTherapeutics, Inc. is fair to Repare shareholders. Upon closing of the proposed transaction, it is estimated that each Repare shareholder will receive a cash payment of $1.82 per share, plus one non-transferable contingent value right enti...
More Repare Therapeutics Inc News

Company Profile

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.

Head office Canada
CEO Steve Forte
Employees 129
Founded 2016
Website www.reparerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today